Interleukin-2 (IL-2) is a T-cellderived 15.5 kDa cytokine which enhances immune function through the increased activity of cytotoxic T lymphocytes, macrophages, natural killer (NK) and lymphokine-activated killer (LAK) cells [ 11. IL-2 also induces the release of the cytokines IL-1 R, IL-4, IL-6, tumour necrosis factor (TNF-a) and interferon (1FN-y) [1, 2] . High-dose systemic recombinant (r) IL-2 therapy is, however, associated with nephrotoxicity [3] . Surgery directly inhibits host anti-tumour activity at a time when malignant cells are shed into the circulation and so predisposes the patient to an increased risk of tumour cell dissemination and metastasis development at surgery [4, 5] . In addition, surgery may also impair renal function [6] . Recent interest, therefore has focused on enhancing the activity of the immune system in the peri-operative period in patients undergoing surgery for cancer by administering rlL-2. We have therefore characterised the resultant nephrotoxicity occurring following the administration of rlL-2 in the peri-operative period.
Eighteen patients were randomized t o receive either rlL-2 (1 8 x lo6 IU/day) or placebo for three days prior to undergoing colonic resection for colorectal cancer (day -3 t o day -1). Urinary indices of renal dysfunction and/or insult were assessed for up to 21 days after surgery. Urinary N-acetyl-8-D-glucosaminidase (NAG), y-glutamyltransferase (yGT), fractional excretion of sodium (FENa) and plasma renin levels were determined [7, 8] . Enzymuria and renin results (mean*SEM) are expressed as units/mmol urinary creatinine and international units/ml, respectively.
Pre-operative rlL-2 was found t o significantly increase, compared with placebo controls, peak NAG (Table 1 ) and yGT enzymuria (5.3k0.6 v 2.4k0.2) and decrease FENa values (maximum difference 0.32k0.06 v 0.76k0.08 %) [all p<O.O5]. Similar, but less pronounced changes in the above parameters were also observed following surgery in the placebo group. Plasma renin levels (Table 1) were significantly elevated, compared t o control values, on days 0 and +l. All values were similar to pretreatment results by the seventh day post-operatively except for NAG enzymuria which remained significantly elevated on day 21. No significant differences in serum sodium, creatinine or urea concentrations, routine estimates of renal function, were noted either pre-or post-operatively in either group.
The increased NAG and yGT enzymuria, reflecting probable proximal renal tubular and brush border insult, and reduced FENa and elevated renin, consistent with a pre-renal extravasation of fluid, observed post surgery following the administration of rlL-2 in the pre-operative period were not associated with decreased "renal function". These results suggest that rlL-2, used t o enhance natural cytotoxicity in the peri-operative period, enhances the renal insult produced following surgery. In this context, serial enzymuria measurements provide a useful adjunct t o clinical management.
